Diabetes & Endocrinology Clinical Trials Update: Week 16, 2026

Published April 17, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

This Phase 3 trial is comparing two drugs, retatrutide and tirzepatide, to see which one is safer and more effective at helping adults with obesity lose weight. The study lasts nearly 89 weeks and involves multiple countries. If retatrutide proves to be better, it could provide a new option for people struggling with obesity to manage their weight more successfully.

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

This study is testing Diamyd, an injection designed to protect insulin-producing cells in adolescents and adults recently diagnosed with type 1 diabetes. The goal is to help preserve their body’s ability to produce insulin and improve blood sugar control. Success in this trial could mean new treatment choices beyond daily insulin injections, especially for patients with a specific genetic marker.

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

This Phase 3 trial is looking at retatrutide’s effects on adults with type 2 diabetes who are also overweight or have obesity. The study aims to see if the drug can help manage both weight and blood sugar at the same time, potentially improving overall health. With about 1000 participants worldwide, the trial runs for almost 89 weeks and could offer a new dual-purpose treatment option.

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

This upcoming Phase 3 trial will test a once-weekly injection called NNC0487-0111 in people who have type 2 diabetes and excess body weight. It will focus on the safety and effectiveness of the medication for weight loss and blood sugar control. Enrollment is planned to include around 630 participants across multiple countries, aiming to provide another option for managing these conditions together.

Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes

This Phase 4 study conducted in Iraq examined how three common oral diabetes treatments affect blood markers linked to diabetes and obesity in adults newly diagnosed with type 2 diabetes. The treatments were given over 12 weeks to see which might best influence these markers. Understanding these effects could help doctors personalize diabetes care more effectively in the future.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.